norfloxacin has been researched along with warfarin in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (21.05) | 18.7374 |
| 1990's | 3 (15.79) | 18.2507 |
| 2000's | 4 (21.05) | 29.6817 |
| 2010's | 7 (36.84) | 24.3611 |
| 2020's | 1 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Alvarez-Pedraglio, A; Colmenarejo, G; Lavandera, JL | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Avdeef, A; Tam, KY | 1 |
| Gozalbes, R; Pineda-Lucena, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Grasela, TH; Green, L; Jolson, HM; Tanner, LA | 1 |
| Bjornsson, TD; Distlerath, LM; Gregg, MH; Rocci, ML; Vlasses, PH; Wheeler, SC; Zing, W | 1 |
| Biasolo, MA; Faggionato, O; Ferrazzi, E; Palù, G; Peracchi, M; Stefanelli, S | 1 |
| Bia, FJ; Divo, AA; Patton, CL; Sartorelli, AC | 1 |
| Linville, T; Matanin, D | 1 |
| Marians, KJ | 1 |
| Howard, BM; Pinney, RJ; Smith, JT | 1 |
| Arsuaga, J; Breier, AM; Brown, PO; Cozzarelli, NR; Khodursky, AB; Peter, BJ | 1 |
| Agrahari, UC; Bhutani, KK; Jachak, SM; Kumari, N; Nandanwar, H; Pahwa, S; Roy, SK | 1 |
| Furubayashi, T; Inoue, D; Katsumi, H; Kawakami, M; Kimura, S; Sakane, T; Takano, K; Tanaka, A; Yamamoto, A; Yamasaki, H | 1 |
| Tanaka, A | 1 |
| Carvalho, DT; Coutinho, HDM; De Menezes, IRA; Dos Santos, FAV; Farias, PAM; Figueredo, FG; Fonteles, MMF; Freitas, TS; Martin, ALAR; Ribeiro-Filho, J; Sousa, AK | 1 |
2 review(s) available for norfloxacin and warfarin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Optimization of Nasal Drug Absorption from Powder Formulations: The Feasibility of Controlling Drug Absorption by the Use of Pharmaceutical Excipients].
Topics: Administration, Intranasal; Cellulose; Drug Compounding; Excipients; Feasibility Studies; Lactose; Nasal Absorption; Nasal Mucosa; Norfloxacin; Piroxicam; Powders; Sodium Chloride; Sumatriptan; Warfarin | 2018 |
1 trial(s) available for norfloxacin and warfarin
| Article | Year |
|---|---|
Norfloxacin does not alter warfarin's disposition or anticoagulant effect.
Topics: Adult; Drug Interactions; Half-Life; Humans; Male; Norfloxacin; Prothrombin Time; Random Allocation; Time Factors; Warfarin | 1990 |
16 other study(ies) available for norfloxacin and warfarin
| Article | Year |
|---|---|
Cheminformatic models to predict binding affinities to human serum albumin.
Topics: Adrenergic beta-Antagonists; Antidepressive Agents, Tricyclic; Chromatography, Affinity; Cyclooxygenase Inhibitors; Databases, Factual; Humans; Hydrophobic and Hydrophilic Interactions; Penicillins; Pharmaceutical Preparations; Protein Binding; Quantitative Structure-Activity Relationship; Reproducibility of Results; Serum Albumin; Steroids | 2001 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
Topics: Animals; Disease Models, Animal; Dogs; Humans; Jejunal Diseases; Kidney Diseases; Models, Biological; Permeability; Porosity; Regression Analysis | 2010 |
QSAR-based solubility model for drug-like compounds.
Topics: Databases, Factual; Models, Molecular; Pharmaceutical Preparations; Quantitative Structure-Activity Relationship; Solubility; Water | 2010 |
Adverse reaction reporting of interaction between warfarin and fluoroquinolones.
Topics: Adult; Aged; Aged, 80 and over; Ciprofloxacin; Drug Interactions; Female; Humans; Male; Middle Aged; Norfloxacin; Product Surveillance, Postmarketing; United States; United States Food and Drug Administration; Warfarin | 1991 |
Antiviral activity of gyrase inhibitors norfloxacin, coumermycin A1 and nalidixic acid.
Topics: Aminocoumarins; BK Virus; Chromatin; Coumarins; Deoxyribonuclease I; Nalidixic Acid; Norfloxacin; Simian virus 40; Topoisomerase II Inhibitors; Virus Replication | 1988 |
Activity of fluoroquinolone antibiotics against Plasmodium falciparum in vitro.
Topics: Aminocoumarins; Animals; Anti-Infective Agents; Chloroquine; Ciprofloxacin; Coumarins; Drug Interactions; Drug Resistance; Enoxacin; Fluoroquinolones; Nalidixic Acid; Norfloxacin; Novobiocin; Ofloxacin; Oxolinic Acid; Pefloxacin; Plasmodium falciparum; Tetracycline; Topoisomerase II Inhibitors | 1988 |
Norfloxacin and warfarin.
Topics: Aged; Aged, 80 and over; Drug Interactions; Female; Humans; Norfloxacin; Prothrombin Time; Warfarin | 1989 |
DNA gyrase-catalyzed decatenation of multiply linked DNA dimers.
Topics: Aminocoumarins; Coumarins; DNA Replication; DNA Topoisomerases, Type II; DNA, Bacterial; DNA, Superhelical; Electrophoresis, Agar Gel; Kinetics; Magnesium; Magnesium Chloride; Norfloxacin; Polymers | 1987 |
Antagonism between bactericidal activities of 4-quinolones and coumarins gives insight into 4-quinolone killing mechanisms.
Topics: Aminocoumarins; Anti-Infective Agents; Ciprofloxacin; Coumarins; DNA Topoisomerases, Type II; Escherichia coli; Genes, Bacterial; Microbial Sensitivity Tests; Mutation; Nalidixic Acid; Norfloxacin; Novobiocin; Ofloxacin; Rifampin | 1994 |
Genomic transcriptional response to loss of chromosomal supercoiling in Escherichia coli.
Topics: Base Composition; Chromosomes, Bacterial; Codon, Initiator; Coumarins; DNA Topoisomerases; DNA, Bacterial; DNA, Superhelical; Enzyme Inhibitors; Escherichia coli K12; Gene Expression Profiling; Gene Expression Regulation, Bacterial; Genes, Bacterial; Kinetics; Mutation; Norfloxacin; Oligonucleotide Array Sequence Analysis; Topoisomerase Inhibitors; Transcription, Genetic | 2004 |
NorA efflux pump inhibitory activity of coumarins from Mesua ferrea.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Clusiaceae; Coumarins; Dose-Response Relationship, Drug; Methicillin-Resistant Staphylococcus aureus; Multidrug Resistance-Associated Proteins; Norfloxacin; Plant Extracts; Staphylococcus aureus | 2013 |
The Enhancement of Nasal Drug Absorption From Powder Formulations by the Addition of Sodium Carboxymethyl Cellulose.
Topics: Absorption, Physiological; Administration, Intranasal; Animals; Carboxymethylcellulose Sodium; Cell Membrane Permeability; Chemistry, Pharmaceutical; Dogs; Madin Darby Canine Kidney Cells; Models, Chemical; Nasal Mucosa; Norfloxacin; Piroxicam; Powders; Rats; Solubility; Warfarin | 2016 |
In vitro and in silico antibacterial evaluation of coumarin derivatives against MDR strains of Staphylococcus aureus and Escherichia coli.
Topics: Anti-Bacterial Agents; Bacteria; Coumarins; Escherichia coli; Humans; Microbial Sensitivity Tests; Norfloxacin; Staphylococcal Infections; Staphylococcus aureus | 2023 |